12,372 trials
COVID-19
Primary: Neutralizing Antibody (Nab) for SARS-CoV-2 Wildtype Virus (Wuhan) Responses Expressed as Geometric Mean Titers (GMT) — 173.2; 159.5; 396.6; 436.0 titers
Atopic Dermatitis (AD)
Primary: Number of Participants With Treatment-emergent Adverse Events (TEAEs) — 42 Participants
Prurigo Nodularis
Primary: Percentage of Participants With ≥ 4- Point Decrease in 7-day Average Worst Itch - Numerical Rating Scale (WI-NRS) up to Week 14 — 24.24; 14.50 percentage of participants…
Type 1 Diabetes · Diabetes
Primary: Change From Baseline in Hemoglobin A1c (HbA1c) at Week 26 [Noninferiority Analysis] — -0.51; -0.56 Percentage of HbA1c
Surgical Site Infection · Colon Surgery · Abdominal Surgery
Primary: To Assess the Anti-infective Efficacy of D-PLEX Over a Period of 30 Days Post Operation, by Preventing Surgical Site Infection (SSI), Defined as Superficial and Deep…
Stroke, Acute
Primary: Number of Participants With Independent Functioning on the Modified Rankin Scale (mRS), as Defined by a Score of 0-2 — 181; 206 Participants
Hunter Syndrome
Primary: Number of Participants With Adverse Events (AEs) — 56 Participants
Cushing Syndrome · Cushing Disease
Primary: Proportions of Participants With Mean Urinary Free Cortisol (mUFC) Categorization Based on Upper Limit of Normal (ULN) — 0; 1; 50; 26 Participants
Relapsing Multiple Sclerosis
Primary: Annualized Relapse Rate (ARR) as Assessed by Confirmed Protocol-defined Adjudicated Relapses — 0.122; 0.130 relapses per participant year — p=0.6691
Venous Thromboembolism
Primary: Recurrent Venous Thromboembolism — 32; 46 Participants
Non-relapsing Secondary Progressive Multiple Sclerosis
Primary: Time to Onset of 6-Month Confirmed Disability Progression (CDP) as Assessed by Expanded Disability Status Scale (EDSS) — 11.97; 12.04 months — p=0.0026
Relapsing Multiple Sclerosis
Primary: Annualized Relapse Rate (ARR) as Assessed by Confirmed Protocol-defined Adjudicated Relapses — 0.109; 0.108 relapses per participant year — p=0.9758
Venous Thrombosis
Primary: Efficacy Outcome - Occurrence of Symptomatic Recurrent Venous Thromboembolism — 1; 2; 2; 2 Participants
Fabry Disease
Primary: Incidence of Treatment-emergent Adverse Events (TEAEs), Serious Adverse Events (SAEs), and AEs (Adverse Events) Leading to Discontinuation of Study Drug — 13; 1; 0…
Caries
Primary: Percent Surface Microhardness Recovery (%SMH Recovery) — 24.4; 51.6; 51.5 Percent Surface Microhardness Recovery — p=0.986